Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05491317 |
TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2022-08-08 |
Location
France
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05487235 |
TitleA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2022-08-04 |
Location
Argentina
Australia Brazil Canada Korea, Republic of New Zealand |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Atezolizumab, GDC-1971, Omeprazole |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05482516 |
TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers | Phase
Phase 3
|
Date Added 2022-08-01 |
Location
District of Columbia, United States
New Jersey, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab, Bevacizumab, Avastin, Tecentriq |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05479812 |
TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2022-07-29 |
Location
Arizona, United States
Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Pembrolizumab, WTX-124 |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05480306 |
TitlePhase 2 Study of DKN-01 in Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-07-29 |
Location
Arizona, United States
California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States Germany Korea, Republic of |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, DKN-01, FOLFIRI, FOLFOX |
Tags
MSS/ MMRp
|
| NCT ID NCT05464030 |
TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Phase
Phase 1
|
Date Added 2022-07-19 |
Location
California, United States
Rhode Island, United States Texas, United States Canada Japan Korea, Republic of Spain |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
M9140 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05438342 |
TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis | Phase
Not Applicable
|
Date Added 2022-06-29 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Chemotherapy，checkpoint immunotherapy, targeted therapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05426005 |
TitleCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2022-06-21 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Cadonilimab |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05425940 |
TitleStudy of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) | Phase
Phase 3
|
Date Added 2022-06-21 |
Location
Alabama, United States
Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Belgium France Germany Hong Kong Hungary Korea, Republic of New Zealand Poland Portugal Singapore Spain Taiwan Thailand United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq |
Tags
MSS/ MMRp
|
| NCT ID NCT05409417 |
TitleExploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | Phase
Phase 2
|
Date Added 2022-06-08 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Unknown status
|
Drugs
Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX |
Tags
MSS/ MMRp
|
